Aclaris Therapeutics Stock Forecast

Sell candidate since Jun 05, 2026

The Aclaris Therapeutics stock price gained 0.93% on the last trading day (Monday, 15th Jun 2026), rising from $4.32 to $4.36. During the last trading day the stock fluctuated 6.69% from a day low at $4.26 to a day high of $4.55. The price has fallen in 5 of the last 10 days but is still up by 0.46% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 552 thousand more shares were traded than the day before. In total, 2 million shares were bought and sold for approximately $7.24 million.

The stock lies in the lower part of a very wide and strong rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $4.15 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift. Given the current short-term trend, the stock is expected to rise 22.98% during the next 3 months and, with a 90% probability hold a price between $5.10 and $6.70 at the end of this 3-month period.

ACRS Signals & Forecast

There are mixed signals in the stock today. The Aclaris Therapeutics stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at $4.54. On a fall, the stock will find some support from the short-term average at $4.31. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. A sell signal was issued from a pivot top point on Wednesday, May 13, 2026, and so far it has fallen -14.34%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume is rising along with the price. This is considered to be a good technical signal.

Support, Risk & Stop-loss for Aclaris Therapeutics stock

Aclaris Therapeutics finds support from accumulated volume at $4.34 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.285 between high and low, or 6.69%. For the last week, the stock has had daily average volatility of 6.67%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (ACRS) For The Upcoming Trading Day Of Tuesday 16th

For the upcoming trading day on Tuesday, 16th we expect Aclaris Therapeutics to open at $4.39, and during the day (based on 14 day Average True Range), to move between $4.23 and $4.49, which gives a possible trading interval of +/-$0.254 (+/-6.01%) up or down from last closing price. If Aclaris Therapeutics takes out the full calculated possible swing range there will be an estimated 6.01% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $4.34 (0.46%) than the resistance at $4.39 (0.69%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Aclaris Therapeutics stock A Buy?

Aclaris Therapeutics holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -1.863 Sell Candidate Unchanged

Predicted Fair Opening Price

Predicted fair opening price on June 16, 2026 - $4.39 ( 0.650%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*
*Your capital is at risk